/The Science Advisory Board (via Qpute.com)
The Science Advisory Board

The Science Advisory Board (via Qpute.com)

The Science Advisory Board<br />

How is the pharma-AI partnership landscape changing?

January 13, 2021 — Artificial intelligence (AI) is taking on a growing role in drug discovery and development, with some 250 firms in a market space that’s worth over $9 billion. And developers of AI are becoming attractive acquisition targets for contract research organizations, according to Ulrik Kristensen, PhD, research analyst and founder of Emersion Insights.

What makes immuno-oncology therapies attractive investments?

January 12, 2021 — Although immuno-oncology therapies have been around for many years, investors are excited to partner with innovators in the space who can push the boundaries of what these therapies are able to achieve. A panel of investors and business development executives discussed what exactly makes a specific candidate attractive as a business opportunity during a recorded session at the Biotech Showcase virtual event.

Tackling the next hurdle in cell and gene therapy: Manufacturing

January 11, 2021 — Although innovation continues to occur at lightning fast speeds in the cell and gene therapy space, commercialization and manufacturing of these technologies is still playing catch-up. A group of investors and executives from across the industry discussed this issue in an on-demand session of the Biotech Showcase virtual event.

How can biopharma innovation be maintained after COVID-19?

January 8, 2021 — Will the speed of biotech innovation seen during the COVID-19 pandemic be maintained going forward, or will the market revert to the status quo? A panel of speakers discussed these questions during a January 7 advance session of the Biotech Showcase, a virtual event to be held January 11-15.

Are biotech companies really high-risk investments?

January 7, 2021 — Despite the public perception of the biotech industry as a high-risk investment, a new analysis published in PLOS One on January 6 found that over the long term, biotech firms that went public performed just as well as nonbiotech companies by various measures of financial success.

Top Operation Warp Speed official shares lessons learned from COVID-19

January 6, 2021 — The global COVID-19 pandemic has placed an urgent burden on governments to serve society, and with the help of the biotechnology and pharmaceutical industries, the job is getting done. That’s according to Moncef Slaoui, PhD, chief adviser of the U.S. government’s Operation Warp Speed project, who discussed his unique experiences at an advance session of the Biotech Showcase virtual event on January 5.

COVID-19 to have long-lasting effect on biotech industry

January 5, 2021 — The COVID-19 pandemic will have a widespread and long-lasting effect on the biotechnology industry, according to speakers at a January 5 presentation held in advance of the Biotech Showcase virtual event taking place January 11-15. Biotech companies have pivoted on a massive scale to pursue infectious disease research — and not all of them will be successful.

Allergic reactions to COVID-19 vaccines shouldn’t stop vaccinations

January 4, 2021 — COVID-19 vaccines currently approved for emergency use by the U.S. Food and Drug Administration are safe even among people with food or medication allergies, according to allergists from Massachusetts General Hospital. A review of all relevant information was published in the Journal of Allergy and Clinical Immunology: In Practice on December 31.

Top 10 ScienceBoard stories for 2020

December 21, 2020 — For many of us, 2020 did not pan out as planned. The emergence of the COVID-19 pandemic has drastically changed our daily lives. Here at ScienceBoard.net, we have provided timely and evidence-based information to our readers regarding COVID-19, as well as many other topics in the biopharmaceutical and life sciences industries.

FDA issues EUA for Moderna COVID-19 vaccine

December 18, 2020 — Just one day after a favorable committee recommendation, the U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for the messenger RNA (mRNA) COVID-19 vaccine from Moderna. The company’s mRNA-1273 vaccine now becomes the second COVID-19 vaccine on the U.S. market, after a vaccine from Pfizer and BioNTech was granted an EUA last week.

New discovery could lead to broad-spectrum antivirals

December 18, 2020 — Scientists have identified a key human gene that is required for cells to consume and destroy viruses. The results of the study were published in Nature on December 16 and could point to new treatments to target viral infections, including COVID-19.

FDA committee votes favorably for Moderna COVID-19 vaccine EUA

December 17, 2020 — Moderna’s messenger RNA (mRNA) COVID-19 vaccine candidate, mRNA-1273, received a favorable recommendation on December 17 from an advisory committee to the U.S. Food and Drug Administration (FDA). The committee’s OK means that mRNA-1273 will probably receive an emergency use authorization (EUA) within days.


This is a syndicated post. Read the original post at Source link .

0 0 vote
Article Rating
Notify of
Inline Feedbacks
View all comments